CKPT Stock - Checkpoint Therapeutics, Inc.
Unlock GoAI Insights for CKPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41,000 | $103,000 | $192,000 | $268,000 | $1.07M |
| Gross Profit | $41,000 | $-43,463,000 | $-49,633,000 | $-48,185,000 | $-15,283,000 |
| Gross Margin | 100.0% | -42197.1% | -25850.5% | -17979.5% | -1429.7% |
| Operating Income | $-56,174,000 | $-52,148,000 | $-58,333,000 | $-56,723,000 | $-23,201,000 |
| Net Income | $-56,240,000 | $-51,847,000 | $-62,624,000 | $-56,617,000 | $-23,081,000 |
| Net Margin | -137170.7% | -50336.9% | -32616.7% | -21125.7% | -2159.1% |
| EPS | $-1.42 | $-2.77 | $-7.09 | $-7.45 | $-4.13 |
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 13th 2025 | D. Boral Capital | Initiation | Buy | $9 |
| July 14th 2022 | B. Riley Securities | Resumed | Buy | $7 |
Earnings History & Surprises
CKPTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 11, 2025 | $-0.02 | — | — | — |
Q2 2025 | May 13, 2025 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.22 | $-0.69 | -213.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.15 | $-0.23 | -53.3% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.29 | $-0.18 | +37.9% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-0.37 | $-0.33 | +10.8% | ✓ BEAT |
Q1 2024 | Mar 22, 2024 | $-0.74 | $-1.10 | -48.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.85 | $-0.29 | +65.9% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.83 | $-1.05 | -26.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.92 | $-0.89 | +3.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-1.31 | $-2.29 | -74.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-1.70 | $-1.20 | +29.4% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-1.70 | $-1.60 | +5.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.10 | $-2.00 | -81.8% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-1.40 | $-3.90 | -178.6% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-1.30 | $-1.40 | -7.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.90 | $-1.20 | -33.3% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-1.30 | $-0.90 | +30.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about CKPT
What is CKPT's current stock price?
What is the analyst price target for CKPT?
What sector is Checkpoint Therapeutics, Inc. in?
What is CKPT's market cap?
Does CKPT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CKPT for comparison